Companies will evaluate Pro-Pharmaceuticals’ delivery technology in combination with Digna’s drugs.

Pro-Pharmaceuticals will apply its carbohydrate technology platform to Digna Biotech’s drugs to achieve improved treatment of chronic hepatitis C infections.

“The collaboration with Digna is an important step in the development, commercialization, and validation of our first-in-class carbohydrate technology,” notes David Platt, Ph.D., president and CEO, Pro-Pharmaceuticals.

Pro-Pharmaceuticals’ Davanat® will be the first to be checked as data from preclinical and clinical trials show that Davanat increased the patient’s exposure to 5-FU 10-fold with no increase in toxicity.

Previous articleOncolytics Biotech Completes Initial Scale-Up of Manufacturing Process for Reolysin
Next articleLumera Extends Deal with MUSC Related to Diagnostic Tests